CDK4/6 inhibitor
CDKN2A/2B deletion
PLK1 inhibitor
chordoma patient’s derived xenograft
palbocicib
volasertib
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
03
06
2022
accepted:
18
10
2022
entrez:
12
12
2022
pubmed:
13
12
2022
medline:
13
12
2022
Statut:
epublish
Résumé
Management of advanced chordomas remains delicate considering their insensitivity to chemotherapy. Homozygous deletion of the regulatory gene From our chordoma xenograft panel, we selected three models, two of them harboring a homozygous deletion of For palbociclib, we observed a significant tumor response for one of two models harboring the deletion of CDK4/6 inhibition appears as a promising strategy to manage advanced chordomas harboring a loss of
Sections du résumé
Background
UNASSIGNED
Management of advanced chordomas remains delicate considering their insensitivity to chemotherapy. Homozygous deletion of the regulatory gene
Methods
UNASSIGNED
From our chordoma xenograft panel, we selected three models, two of them harboring a homozygous deletion of
Results
UNASSIGNED
For palbociclib, we observed a significant tumor response for one of two models harboring the deletion of
Conclusion
UNASSIGNED
CDK4/6 inhibition appears as a promising strategy to manage advanced chordomas harboring a loss of
Identifiants
pubmed: 36505864
doi: 10.3389/fonc.2022.960720
pmc: PMC9732546
doi:
Types de publication
Journal Article
Langues
eng
Pagination
960720Informations de copyright
Copyright © 2022 Passeri, Dahmani, Masliah-Planchon, El Botty, Courtois, Vacher, Marangoni, Nemati, Roman-Roman, Adle-Biassette, Mammar, Froelich, Bièche and Decaudin.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Cancer Discov. 2020 Aug;10(8):1174-1193
pubmed: 32404308
Cells. 2020 Sep 01;9(9):
pubmed: 32883024
Br J Cancer. 2001 May 18;84(10):1424-31
pubmed: 11355958
Neurosurgery. 2020 Feb 1;86(2):E118-E123
pubmed: 31504814
Neoplasia. 2012 Sep;14(9):788-98
pubmed: 23019410
Cancer Metastasis Rev. 2016 Dec;35(4):547-573
pubmed: 28025748
PLoS One. 2014 Feb 04;9(2):e87663
pubmed: 24503940
J Exp Clin Cancer Res. 2020 Nov 26;39(1):262
pubmed: 33243298
JCO Precis Oncol. 2020 Nov;4:757-766
pubmed: 35050752
J Clin Oncol. 2009 Jul 1;27(19):3154-60
pubmed: 19451429
Cancers (Basel). 2022 Mar 14;14(6):
pubmed: 35326637
Neurooncol Adv. 2020 Dec 08;3(1):vdaa173
pubmed: 33543146
Acta Pharm Sin B. 2021 Jan;11(1):30-54
pubmed: 33532179
Front Pharmacol. 2020 Nov 16;11:580251
pubmed: 33364954
Genes Chromosomes Cancer. 2016 Jul;55(7):591-600
pubmed: 27072194
Precis Clin Med. 2018 Jun;1(1):29-48
pubmed: 30687561
Lancet Oncol. 2021 Feb;22(2):212-222
pubmed: 33460574
J Neuropathol Exp Neurol. 2020 Mar 1;79(3):314-324
pubmed: 31841164
Clin Cancer Res. 2019 Apr 1;25(7):2064-2071
pubmed: 30642912
Mol Cancer Ther. 2020 Aug;19(8):1719-1726
pubmed: 32430489
PLoS One. 2014 Jul 01;9(7):e101283
pubmed: 24983247
Nat Commun. 2021 Feb 3;12(1):757
pubmed: 33536423
Genes Chromosomes Cancer. 2001 Nov;32(3):203-11
pubmed: 11579460
Int J Oncol. 2012 Feb;40(2):443-51
pubmed: 22002331
Lancet Oncol. 2015 Feb;16(2):e71-83
pubmed: 25638683
Oncotarget. 2021 Apr 13;12(8):859-872
pubmed: 33889306
J Hematol Oncol. 2020 Jul 28;13(1):104
pubmed: 32723346
Sarcoma. 2010;2010:630129
pubmed: 21253487
Anticancer Drugs. 2009 Nov;20(10):953-5
pubmed: 19730087
Int J Cancer. 2020 Jan 1;146(1):10-17
pubmed: 31396957
Eur J Cancer. 2015 Nov;51(17):2609-14
pubmed: 26283036
Nat Commun. 2017 Oct 12;8(1):890
pubmed: 29026114
Onco Targets Ther. 2020 May 25;13:4649-4663
pubmed: 32547095
Cancer Res. 2021 Nov 1;81(21):5572-5581
pubmed: 34518211
J Clin Med. 2021 Mar 04;10(5):
pubmed: 33806339
J Immunother Cancer. 2020 Jun;8(1):
pubmed: 32581056
Ann Oncol. 2013 Jul;24(7):1931-1936
pubmed: 23559153
Sci Rep. 2020 Jul 31;10(1):12982
pubmed: 32737414
J Invest Dermatol. 2015 Oct;135(10):2475-2483
pubmed: 26016894
J Pathol. 2021 Sep;255(1):72-83
pubmed: 34124783
J Clin Oncol. 2012 Mar 20;30(9):914-20
pubmed: 22331945
Front Oncol. 2022 Sep 29;12:997506
pubmed: 36248987
Neuro Oncol. 2022 Mar 12;24(3):442-454
pubmed: 34614192
Cell Cycle. 2009 Dec;8(23):3984-4001
pubmed: 19923890
PLoS One. 2011;6(5):e18846
pubmed: 21602918
Leukemia. 2015 Jan;29(1):11-9
pubmed: 25027517
J Orthop Res. 2012 Oct;30(10):1666-73
pubmed: 22504929
Eur J Cancer. 2017 Jul;79:119-128
pubmed: 28478340
World Neurosurg. 2014 Nov;82(5):806-14
pubmed: 25009165
Mol Cancer Ther. 2016 Jul;15(7):1427-35
pubmed: 27330107
J Neurosurg. 2011 Oct;115(4):760-9
pubmed: 21699479
Am J Pathol. 2018 Dec;188(12):2902-2911
pubmed: 30248342
Cancer. 2018 Oct 15;124(20):4056-4063
pubmed: 30216418
Carcinogenesis. 2001 Sep;22(9):1521-6
pubmed: 11532875
Annu Rev Pathol. 2015;10:145-71
pubmed: 25387058
Cell Cycle. 2011 Aug 1;10(15):2497-503
pubmed: 21775818
Nature. 1994 Apr 21;368(6473):753-6
pubmed: 8152487
Science. 1956 Aug 10;124(3215):269-70
pubmed: 13351639
Cancer Res. 2015 Sep 15;75(18):3823-31
pubmed: 26183925
Cells. 2020 Mar 10;9(3):
pubmed: 32164162
J Pathol Clin Res. 2020 Apr;6(2):113-123
pubmed: 31916407
Acta Oncol. 2009;48(1):158-9
pubmed: 18752082
Curr Biol. 2007 Feb 20;17(4):316-22
pubmed: 17291758
Front Oncol. 2018 Nov 02;8:500
pubmed: 30456204
Ann Oncol. 2017 Jun 1;28(6):1230-1242
pubmed: 28184416
Nat Commun. 2020 Aug 13;11(1):4053
pubmed: 32792481
Ann Oncol. 2009 Nov;20(11):1886-94
pubmed: 19570961
Sci Rep. 2017 Aug 23;7(1):9226
pubmed: 28835717
World Neurosurg. 2018 Jan;109:307-327
pubmed: 29045855
Int J Cancer. 2019 Sep 1;145(5):1179-1188
pubmed: 30478914